Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

Highlights

• The LIDA trial demonstrates that 3 months of romosozumab followed by 9 months of denosumab is non-inferior to 12 months of continuous romosozumab for total hip BMD gains.
• This abbreviated approach leverages the early, most potent ‘anabolic window’ of romosozumab while reducing the cumulative burden of cost and cardiovascular risk.
• The findings support a paradigm shift toward more flexible, physiology-based dosing in high-risk postmenopausal osteoporosis.

Background: The Challenge of Sustained Anabolic Therapy

Postmenopausal osteoporosis represents a significant global health burden, characterized by reduced bone mass and microarchitectural deterioration. The standard of care for patients at very high risk of fracture has shifted toward initiating therapy with anabolic agents. Romosozumab, a humanized monoclonal antibody that binds to and inhibits sclerostin, has emerged as a uniquely potent agent due to its dual effect: stimulating bone formation while simultaneously inhibiting bone resorption.

However, clinical trials such as FRAME and ARCH have consistently shown that romosozumab’s bone-forming effect is transient, peaking early and waning significantly after 6 to 12 months. Furthermore, the drug is expensive, requires monthly clinician-administered injections, and carries a boxed warning regarding potential cardiovascular risks (myocardial infarction and stroke). These factors have created a clinical need to determine whether the benefits of romosozumab can be captured in a shorter treatment window without compromising long-term BMD gains.

Key Content: Evidence from the LIDA Trial

Mechanistic Basis: The Sclerostin-Wnt Pathway

Sclerostin, produced primarily by osteocytes, acts as a negative regulator of bone formation by antagonizing the Wnt signaling pathway. By inhibiting sclerostin, romosozumab releases this brake, leading to rapid osteoblast activation. Interestingly, bone histomorphometry studies have shown that the anabolic ‘surge’ is most pronounced in the first 90 days. As the body adapts to sclerostin inhibition—potentially through compensatory up-regulation of other Wnt inhibitors like DKK1—the net anabolic benefit diminishes, leaving primarily the antiresorptive effect in the latter half of a standard 12-month course.

Study Design and Patient Population

The LIDA (Leder et al.) trial was an open-label, randomized, non-inferiority trial conducted at a single US academic medical center. The study enrolled 50 postmenopausal women (mean age 69.6 years) at high risk of fracture. Participants were randomized into two groups:

• The 3-month ROMO Group: 3 months of romosozumab (210 mg/month) followed by 9 months of denosumab (60 mg every 6 months).
• The 12-month ROMO Group: 12 months of continuous romosozumab (210 mg/month).

The transition to denosumab in the experimental arm was strategically designed to ‘lock in’ the early anabolic gains, as denosumab is a potent antiresorptive (RANKL inhibitor) known to maintain or further increase BMD following anabolic stimulation.

Primary and Secondary Outcomes

The primary endpoint was the 12-month percentage change in total hip BMD. The results showed:

• 3-month ROMO Group: 5.7% (SD 3.3) increase.
• 12-month ROMO Group: 6.0% (SD 3.2) increase.

The difference was well within the prespecified 2% non-inferiority margin. Secondary endpoints, including lumbar spine BMD, also showed robust increases in both groups. These data suggest that the vast majority of romosozumab’s BMD-increasing potential is achieved within the first quarter of the standard treatment duration when followed by a potent antiresorptive.

Safety and Adverse Events

Safety monitoring revealed that adverse events were balanced between the two regimens. Common reports included back pain, fatigue, and injection site reactions. Notably, no significant difference in cardiovascular events was observed in this small cohort, though a larger trial would be required to definitively confirm the safety benefits of an abbreviated course.

Expert Commentary: Clinical Implications and Limitations

The LIDA trial provides a compelling proof-of-concept for ‘front-loading’ anabolic therapy. From a health policy perspective, reducing romosozumab use from 12 months to 3 months could decrease the drug cost by 75% per patient, significantly broadening access in resource-constrained environments. Furthermore, for patients with pre-existing cardiovascular risk factors who might otherwise be excluded from romosozumab therapy, a 3-month exposure may represent a more acceptable risk-benefit ratio.

However, several caveats remain. The trial size (n=50) is relatively small, and while non-inferiority for BMD was met, BMD is a surrogate marker for fracture risk. Large-scale fracture endpoint trials are the gold standard for changing international guidelines. Additionally, the open-label nature of the trial introduces potential bias, although BMD measurements are objective. Experts also debate whether 3 months is the absolute ‘sweet spot’ or if 6 months might provide a slightly better margin of safety for BMD accrual in patients with more severe osteoporosis.

Conclusion: Toward a New Standard of Care

The LIDA trial marks a significant step toward personalized medicine in osteoporosis. It confirms that the early anabolic effects of romosozumab are potent enough to drive significant BMD gains that can be successfully maintained by denosumab. This abbreviated 3-month regimen addresses major barriers to romosozumab use, including cost and patient burden, without sacrificing clinical efficacy in hip BMD. Future research should focus on long-term fracture outcomes and the exploration of this abbreviated regimen in broader, more diverse patient populations.

References

• Leder BZ, Ramchand SK, Jordan M, et al. 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol. 2026;14(3):216-222. PMID: 41621431.
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532-1543. PMID: 27641194.
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417-1427. PMID: 28892457.